Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 18 - Horizontal Merger Policy

  • from Part V - Mergers and Acquisitions
  • Roger D. Blair, University of Florida, Christine Piette Durrance, Tirza J. Angerhofer, Duke University, North Carolina
  • Book:
    Antitrust Policy in Health Care Markets
    Published online:
    24 November 2022
    Print publication:
    08 December 2022, pp 405-433

  • Summary

    In this chapter, we review the tools and tactics competition authorities use to evaluate the competitive consequences of mergers using various examples. Merger policy in the United States is governed by Section 7 of the Clayton Act, which forbids mergers that are apt to impair competition or tend to create a monopoly. Since Section 7 is a preventive – rather than a remedial – provision, the antitrust Agencies need not demonstrate actual harm. The Agencies need only prove that the adverse effects are likely to accompany that merger. A careful review of the change in the market structure before and after the proposed merger is often employed to determine the likelihood of an adverse effect. We illustrate the Agencies’ methodology by looking at mergers of health insurers, physician groups, and pharmaceutical companies.